Researchers are excitedly examining retatrutide, a promising drug created by Eli Lilly, as a potential breakthrough in body reduction . Distinct from many earlier approaches, retatrutide is a twin-action agonist targeting equally GLP-1 and GIP, hormones that affect appetite and blood glucose control